Home » Stocks » Emergent BioSolutions

Emergent BioSolutions, Inc. (EBS)

Stock Price: $133.42 USD -1.52 (-1.13%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
After-hours: $135.79 +2.37 (1.78%) Aug 14, 6:21 PM

Stock Price Chart

Key Info

Market Cap 7.06B
Revenue (ttm) 1.26B
Net Income (ttm) 170.30M
Shares Out 52.92M
EPS (ttm) 3.19
PE Ratio 41.82
Forward PE 20.00
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $133.42
Previous Close $134.94
Change ($) -1.52
Change (%) -1.13%
Day's Open 134.90
Day's Range 131.60 - 136.02
Day's Volume 792,840
52-Week Range 39.11 - 137.61

More Stats

Market Cap 7.06B
Enterprise Value 7.58B
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 52.92M
Float 44.87M
EPS (basic) 3.27
EPS (diluted) 3.19
FCF / Share 3.69
Dividend n/a
Dividend Yield n/a
Earnings Yield 2.39%
FCF Yield 2.75%
Payout Ratio n/a
Shares Short 2.61M
Short Ratio 2.14
Short % of Float 6.88%
Beta 1.42
PE Ratio 41.82
Forward PE 20.00
P/FCF Ratio 36.40
PS Ratio 5.61
PB Ratio 5.77
Revenue 1.26B
Operating Income 262.80M
Net Income 170.30M
Free Cash Flow 194.00M
Net Cash -518.20M
Net Cash / Share -9.79
Gross Margin 38.36%
Operating Margin 20.87%
Profit Margin 13.50%
FCF Margin 15.41%
ROA 7.83%
ROE 15.57%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 6
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$113.83*
(-14.68% downside)
Low
95.0
Current: $133.42
High
144.0
Target: 113.83
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue1,106782561489489404313282273286
Revenue Growth41.36%39.49%14.75%-0.11%20.98%29.33%10.95%3.11%-4.47%-
Gross Profit673460373363382303251236231239
Operating Income11489.8012410614289.1942.8029.9732.1073.56
Net Income54.5062.7082.6051.8062.8736.7431.1423.5223.0251.70
Shares Outstanding51.5050.1041.8040.2038.6037.3436.2036.0835.6631.78
Earnings Per Share1.041.221.711.131.410.880.850.650.641.59
EPS Growth-14.75%-28.65%51.33%-19.86%60.23%3.53%30.77%1.56%-59.75%-
Operating Cash Flow18841.8020854.6042.5211296.9739.6412.1998.02
Capital Expenditures-86.90-72.10-54.80-76.20-44.81-30.67-42.02-53.85-54.03-22.10
Free Cash Flow101-30.30153-21.60-2.3081.6554.95-14.20-41.8475.92
Cash & Equivalents168112179272308280179142146171
Total Debt81179513.5026824725162.0062.7759.4547.43
Net Cash / Debt-643-6821663.4261.4129.5011778.8986.63124
Assets2,3272,2291,0709701,037939627564547500
Liabilities1,2391,219158374377385137122130127
Book Value1,0891,011912596660553490441414369
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Emergent BioSolutions, Inc.
Country United States
Employees 1,834
CEO Robert G. Kramer

Stock Information

Ticker Symbol EBS
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NYSE: EBS
IPO Date November 15, 2006

Description

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, the company offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, it offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.